Edition:
India

Profile: Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

1.75EUR
17 Sep 2019
Change (% chg)

€-0.05 (-2.56%)
Prev Close
€1.80
Open
€1.77
Day's High
€1.81
Day's Low
€1.75
Volume
73,065
Avg. Vol
57,247
52-wk High
€3.30
52-wk Low
€1.65

Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The Company also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The Company's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The Company's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).

Company Address

Transgene SA

400 Boulevard Gonthier d'Anderna
Parc d'Innovation - CS80166
ILLKIRCH-GRAFFENSTADEN     67405
P: +333.88279100
F: +333.88279111

Company Web Links